Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Builds Up Trodelvy Data In TNBC Ahead Of Competition

Sep 16 2021

• By Alaric DeArment

Doctor with Mammography - Image — Gilead presented data on Trodelvy in triple-negative breast cancer at the ESMO meeting on 16 September • Source: Shutterstock

Related Content

Gilead Teases Big Cancer Drug Readouts In Second Half

Jul 30 2021

AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer

May 10 2021

Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal

Sep 14 2020

AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi

Jul 27 2020

Pipeline Watch: Phase III Readouts For COVID-19, Dry Eye Disease, Uveal Melanoma

Apr 16 2021

Related Companies

Gilead Sciences, Inc.

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Seagen Inc.

Additional Topics

Biologics Clinical Trials Research & Development Cancer

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window